"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A trial looking at olaparib and AZD5363 for people with cancer that has come back or spread elsewhere in the body (ComPAKT)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at a combination of 2 drugs called olaparib and AZD5363 for people who have a solid tumour for which there is no other treatment available. A solid tumour is any type of cancer other than
More about this trial
Olaparib is a drug you take by mouth. It targets and blocks a protein called PARP (it is a PARP inhibitor). PARP repairs damage to
Research in the laboratory has shown that olaparib and AZD5363 together might stop cancer growing. In this trial, researchers want to see if this drug combination helps people by shrinking advanced cancer.
The trial is in 2 parts. People with any type of solid tumour can join the first part of the trial. In the second part, the researchers will be looking for people with certain gene changes including people who have changes (mutations) to genes called BRCA1 or BRCA2.
The aims of the trial are to
- Find the highest dose of AZD5363 you can have with olaparib
- Learn more about the side effects of both drugs
- See what effects the drugs have on the body
Who can enter
You may be able to join this trial if all of the following apply
- You have a solid tumour (any type of cancer except leukaemia) that has come back or spread elsewhere in your body
- There is no suitable
standard treatmentavailable for you
- You have an area of cancer that the doctor can measure
- You are well enough to carry out all your normal activities, apart from heavy physical work (performance status of 0 or 1)
- You have satisfactory blood test results
- You are over 18 years of age
- You are willing to use reliable contraception during the trial and for 6 months afterwards if there is any chance you or your partner could become pregnant (women who could possibly become pregnant must also use reliable contraception for 4 weeks before joining the trial)
You cannot enter this trial if you
- Have cancer that has spread to your brain or is pressing on your spinal cord (spinal cord compression) unless you are free from symptoms and have not taken steroids in the last 4 weeks
- Have had radiotherapy (apart from radiotherapy for symptoms) in the last 4 weeks
- Have had hormone therapy in the last 4 weeks (if you are having hormone therapy for prostate cancer you may be able to take part)
- Have had surgery,
immunotherapyor chemotherapy in the last 4 weeks. If you have had chemotherapy with either nitrosoureasor Mitomcyin C this must have been in the last 6 weeks
- Are taking part in any other trial looking at an experimental drug, or have had another experimental drug in the last 4 weeks
- Have not recovered from the side effects of other treatment unless they are very mild – the trial doctors can advise you about this
- Have any type of
- Have diabetes or much higher than normal levels of sugar in your blood
- Have a high level of protein in your urine (your doctor can check for this)
- Have had a heart attack in the last 6 months or have any other heart condition that is a cause for concern (the trial doctors can advise you about this)
- Have a problem with your
digestive systemor uncontrolled sickness that may affect how you absorb drugs (your doctor can advise you about this)
- Are unable to swallow tablets or capsules
- Are known to be allergic or very sensitive to olaparib or AZD5363, or to similar drugs (or anything they contain)
- Have had any medication that affects the CYP3A4 enzyme in the last 2 weeks (your doctor can advise you about this)
- Have had St John’s Wort in the last 3 weeks
- Have a condition that means you are at risk of bleeding (bleeding diathesis)
- Have an active infection with HIV, hepatitis B or hepatitis C
- Have another serious medical condition or mental health problem that the trial team think could affect your taking part
- Are pregnant or breastfeeding
This is a phase 1 trial. It is in 2 parts. For part 1 the researchers need about 12 to18 people to take part. For part 2 they will need about 40 people.
The aim of the first part of the trial is to find out the best dose of AZD5363 that you can have with olaparib. You will be put into 1 of 2 groups. People in both groups take olaparib twice a day throughout the trial. Then
- One group have AZD5363 twice a day for 4 days each week (with 3 days off)
- One group have AZD5363 twice a day for 2 days each week (with 5 days off)
Olaparib is a tablet and AZD5363 is a capsule. From November 2014 all patients having AZD5363 will have this as a tablet. Your dose of AZD5363 will be increased twice if you don’t have any bad side effects.
Once the researchers have established the best dose of AZD5363, they will move into the second part of the trial. The aim of this part is to find out more about how the combination of the 2 drugs works. The researchers will be looking for people with certain gene changes, including people who have changes to genes called BRCA1 or BRCA2.
The researchers will work out the best way to take AZD5363 in the first part of the trial. If you join the second part, the researchers will tell you when to take both drugs.
The researchers may ask you to have a
You can have treatment
- For as long as it is helping you and your cancer has not grown
- Until you decide you don’t want to continue with the trial
- Until your trial doctor feels its best for you to stop the trial
You see the trial team and have some tests before you start treatment. The tests include
- Physical examination
- Blood tests
- Urine tests
- CT scan or MRI scan
- Heart trace (
- Heart scan (
echocardiogram) or MUGA scan
You may also have a bone scan.
You need to go to hospital regularly during treatment. During your hospital visits you will have a physical examination and blood and urine tests to check your general health. The doctors will also ask you to have a mouth (buccal) swab.
You have a heart trace (ECG) on the 1st day of treatment, at the end of the 1st week, then every 3 weeks.
You have a heart scan (an echocardiogram or MUGA scan) after 3 weeks.
You may be in a group where the researchers are looking more closely at the levels of the drugs in your body. This is called
If you agreed to have a sample of your cancer (
About every 9 weeks you will have a CT or MRI scan so that the doctors can measure your cancer. You may also have some blood tests to check for
AZD5363 can increase the levels of sugar in your body. The trial team will ask you to do a urine test twice a week to check for sugar.
When you finish the trial treatment you go to hospital about 4 weeks later for a check up and a repeat of the tests you had before you started treatment.
As olaparib and AZD5363 are new drugs, there may be side effects we don’t know about yet. The known side effects for both drugs are
- Tiredness (fatigue)
- Loss of appetite
- Skin rash
- Feeling or being sick
- A sore mouth
- An effect on your liver causing yellowing of your skin or eyes, itching or tummy pain (
- Heart problems, including a faster heart beat and a change to the heart rhythm
- Tummy (abdominal) pain
- An effect on your kidneys
AZD5363 can also
- Cause an allergic reaction including an itchy rash, high temperature (fever) and swelling of your face. You must tell your doctor straight away if you have any of these
- Increase in the amount of sugar in your blood
- Make you more sensitive to sunlight
Olaparib can also cause
- A drop in blood cells causing an increased risk of infection, bleeding problems, tiredness and breathlessness
- Weakness and dizziness
How to join a clinical trial
Dr Timothy Yap
Cancer Research UK
Institute of Cancer Research (ICR)
NIHR Clinical Research Network: Cancer
Royal Marsden NHS Foundation Trust
This is Cancer Research UK trial number CRUKD/14/004.